My Library

University LibraryCatalogue


LEADER 00000nam a2200433 a 4500 
001    000011956910 
005    20000917191231.0 
008    951005t19961996pau      b    001 0 eng   
010    95042306 //r96 
019 1  11956910 
020    0812232577|q(alk. paper) 
020    0812232577 
035    .b26357094 
040    TOC|beng|cTOC 
043    n-us--- 
050 00 KF1297.D7|bG74 1996 
082 00 346.7303/8|220 
082 00 347.30638|220 
100 1  Green, Michael D.,|d1950-|0http://id.loc.gov/authorities/
       names/n95099046 
245 10 Bendectin and birth defects :|bthe challenges of mass 
       toxic substances litigation /|cMichael D. Green. 
264  1 Philadelphia :|bUniversity of Pennsylvania Press,|c[1996] 
264  4 |c©1996 
300    xiii, 368 pages ;|c24 cm 
336    text|btxt|2rdacontent 
337    unmediated|bn|2rdamedia 
338    volume|bnc|2rdacarrier 
504    Includes bibliographical references (pages [353]-359) and 
       index. 
505 0  1. A Birth Defect Child Is Born -- 2. Locating Bendectin 
       Within the Mass Toxic Landscape -- 3. The Science of 
       Determining Toxic Causation -- 4. The Food and Drug 
       Administration -- 5. The Wm. S. Merrell Company -- 6. A 
       Mother's Quest -- 7. The Mekdeci Case -- 8. The Unraveling
       of Mekdeci -- 9. The Proliferation of Bendectin Litigation
       -- 10. Litigating a Multidistrict Case -- 11. The 
       Withdrawal of Bendectin -- 12. Forging a Mass Toxic 
       Substances Trial -- 13. The Settlement and Unsettlement of
       MDL-486 -- 14. The MDL-486 Trial -- 15. Aggregative 
       Procedure in Mass Toxic Substances Litigation -- 16. The 
       Third Phase of Bendectin Litigation: Oxendine Richardson, 
       and the Individual Trials -- 17. The Legacy of Bendectin 
       for Toxic Causation Law -- 18. The Lessons and Non-Lessons
       of Bendectin Litigation. 
520    Benedictin was prescribed to more than thirty-five million
       American women from its introduction in 1956 until 1983, 
       when it was withdrawn from the market. The drug's 
       manufacturer, Merrill Dow Pharmaceuticals, a major U.S. 
       pharmaceutical firm, joined a list of other companies 
       whose product liabilities would result in precedent-
       setting litigation. Before it was over, the Benedictin 
       litigation would involve 2,000 claimants over a fifteen-
       year period. Michael D. Green offers a comprehensive 
       overview of the Benedictin case and highlights many of the
       key issues in mass toxic substances litigation. 
650  0 Products liability|xDrugs|zUnited States.|0http://
       id.loc.gov/authorities/subjects/sh2010108567 
650  0 Toxic torts|zUnited States.|0http://id.loc.gov/authorities
       /subjects/sh2008112923 
650  0 Complex litigation|zUnited States.|0http://id.loc.gov/
       authorities/subjects/sh2008101023 
650  0 Bendectin (Trademark)|0http://id.loc.gov/authorities/
       subjects/sh95008520|xToxicology.|0http://id.loc.gov/
       authorities/subjects/sh2002007679 
650  0 Abnormalities, Human.|0http://id.loc.gov/authorities/
       subjects/sh85000182 
907    .b26357094 
984    VU|cheld 
990    MARCIVE MELB 201906 
Location Call No. Status
 UniM Law  KN 39 P6 G1 GREE    AVAILABLE